缺血靶向冠状动脉血运重建改善颈动脉内膜切除术后5年生存
该观察性队列研究比较了术前采用冠状动脉计算机断层扫描衍生血流储备分数(FFRCT)检测无症状冠状动脉缺血并术后行缺血靶向血运重建的患者与仅接受标准心脏评估的匹配对照。FFRCT组5年全因死亡、心源性死亡、心肌梗死和主要不良心血管事件均低于对照组,生存率更高。
要点
- FFRCT组5年全因死亡11% vs 对照组24%(HR 0.37,95%CI 0.17-0.77;P=.016)。
- FFRCT组5年心源性死亡3% vs 对照组13%(HR 0.15,95%CI 0.03-0.69;P=.009)。
- FFRCT组5年心肌梗死3% vs 对照组21%(HR 0.07,95%CI 0.02-0.31;P<.001)。
核心结论
- 诊断无症状冠状动脉缺血并在颈动脉内膜切除术后行择期缺血靶向冠状动脉血运重建,可使5年全因死亡、心源性死亡、心肌梗死和主要不良心血管事件风险降低超过50%,并改善生存(89% vs 76%)。
研究设计与样本
- 观察性队列研究,纳入无心脏病史或冠状动脉症状并接受择期颈动脉内膜切除术的患者;FFRCT组100例,对照组100例,两组在年龄、性别、合并症或颈动脉内膜切除术指征方面匹配良好,无显著差异。
- FFRCT组患者参与一项术前使用冠状动脉计算机断层扫描衍生血流储备分数(FFRCT)检测无症状冠状动脉缺血并术后行择期缺血靶向冠状动脉血运重建的前瞻性研究;对照组接受标准术前心脏评估且未行择期冠状动脉血运重建。
- 病变特异性冠状动脉缺血定义为狭窄>30%远端FFRCT≤0.80,严重缺血定义为FFRCT≤0.75;随访5年,终点包括全因死亡、心源性死亡、心肌梗死、卒中和主要不良心血管事件(MACE,定义为心血管死亡、心肌梗死或卒中)。
主要发现
- FFRCT组中57%存在无症状病变特异性冠状动脉缺血(FFRCT≤0.80),44%为严重缺血,7%为左主干缺血;43%无冠状动脉缺血(FFRCT>0.80);对照组冠状动脉缺血状态未知。
- 两队列均成功完成颈动脉内膜切除术,无死亡或神经系统事件,所有患者均接受最佳术后药物治疗;FFRCT组33%在颈动脉内膜切除术后3个月内行择期缺血靶向冠状动脉血运重建,对照组未行择期冠状动脉血运重建。
- 5年随访期间,与对照组相比,FFRCT组全因死亡更少(11% vs 24%;HR 0.37;95%CI 0.17-0.77;P=.016);心源性死亡更少(3% vs 13%;HR 0.15;95%CI 0.03-0.69;P=.009);心肌梗死更少(3% vs 21%;HR 0.07;95%CI 0.02-0.31;P<.001);MACE更少(10% vs 33%;HR 0.21;95%CI 0.10-0.44;P<.001),卒中无差异。
- 无冠状动脉缺血(FFRCT>0.80)的患者中无心源性死亡或心肌梗死;FFRCT组年死亡率为2.2%/年,对照组为4.8%/年。
关键数值与推荐
- 病变特异性冠状动脉缺血定义为狭窄>30%远端FFRCT≤0.80,严重缺血定义为FFRCT≤0.75。
- MACE定义为心血管死亡、心肌梗死或卒中。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: Long-term survival after carotid endarterectomy (CEA) is limited by adverse cardiac events with 5% annual mortality. We sought to determine whether diagnosis of silent coronary ischemia together with elective ischemia-targeted coronary revascularization can reduce death and myocardial infarction (MI) and improve long-term survival of patients after CEA. METHODS: Observational cohort study of patients with no cardiac history or coronary symptoms undergoing elective CEA. Patients enrolled in a prospective study of preoperative cardiac evaluation using coronary computed tomography-derived fractional flow reserve (FFRCT) to detect silent (asymptomatic) coronary ischemia together with elective postoperative ischemia-targeted coronary revascularization were compared with matched controls with standard preoperative cardiac evaluation and no elective coronary revascularization. Lesion-specific coronary ischemia was defined as an FFRCT of ≤0.80 distal to >30% stenosis with severe ischemia defined as an FFRCT of ≤0.75. End points included all-cause death, cardiac death, MI, stroke, and major adverse cardiovascular events (MACE) (defined as cardiovascular death, MI, or stroke) during 5 years of follow-up. RESULTS: FFRCT (n = 100) and control (n = 100) cohorts were well-matched with no significant differences in age, gender, comorbidities, or indications for CEA. Asymptomatic lesion-specific coronary ischemia (FFRCT of ≤0.80) was present in 57% of FFRCT patients, with severe ischemia in 44% and left main ischemia in 7%; 43% had no coronary ischemia (FFRCT of >0.80). The status of coronary ischemia was unknown in the controls. CEA was performed successfully in both cohorts with no deaths or neurological events, and all patients received optimal postoperative medical therapy. Elective ischemia-targeted coronary revascularization was performed in 33% of FFRCT patients within 3 months of CEA. Controls had no elective coronary revascularization. During 5 years of follow-up, compared with controls, the FFRCT group had fewer all-cause deaths (11% vs 24%; hazard ratio [HR], 0.37; 95% confidence interval [CI], 0.17-0.77; P = .016); fewer cardiac deaths (3% vs 13%; HR, 0.15; 95% CI, 0.03-0.69; P = .009); fewer MIs (3% vs 21%; HR, 0.07; 95% CI, 0.02-0.31; P < .001), and fewer MACEs (10% vs 33%; HR, 0.21; 95% CI, 0.10-0.44; P < .001) with no differences in stroke. There were no cardiac deaths or MIs among patients with no coronary ischemia (FFRCT of >0.80). Annual mortality in FFRCT was 2.2% per year compared with 4.8% per year in controls. CONCLUSIONS: Diagnosis of silent coronary ischemia together with elective ischemia-targeted coronary revascularization after CEA decrease the 5-year risk of all-cause death, cardiac death, MI, and MACE by >50% and improved survival (89%) compared with patients receiving standard cardiac evaluation and care (76%).
引用
- Krievins D, Jegere S, Latkovskis G, et al. Ischemia targeted coronary revascularization improves 5-year survival following carotid endarterectomy. J Vasc Surg. 2025. PMID: 40158755. doi:10.1016/j.jvs.2025.03.197
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。